Sign up to save your podcasts
Or
Share Catalent commits to ADCs by upping its stake in Redwood
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Catalent commits to ADCs by upping its stake in Redwood
Catalent has increased its stake in Redwood Biosciences telling us it is committed to the development of antibody-drug conjugates (ADCs) and the SMARTag technology platform.
View all episodes
By William Reed LtdCatalent has increased its stake in Redwood Biosciences telling us it is committed to the development of antibody-drug conjugates (ADCs) and the SMARTag technology platform.